Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 1/20 | 0.58 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.52 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.52 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | CASP1 | P29466 | 1/20 | 0.46 |
| ▸ | CASP7 | P55210 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | BCHE | P06276 | 1/20 | 0.45 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | PDE5A | O76074 | 2/20 | 0.42 |
| ▸ | PRKCB | P05771 | 1/20 | 0.42 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.42 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3868594 | 0.78 | CYP2D6 (0.53) | CHRNA7ADRA1AADRA1DADRA1BPOLB | |
| SCHEMBL14364159 | 0.76 | CHRNA7 (0.55) | CHRNA7ADRA1AADRA1DADRA1BPOLB | |
| SCHEMBL30229697 | 0.74 | CHRNA7 (0.56) | CHRNA7ADRA1AADRA1DADRA1BPOLB | |
| SCHEMBL11355035 | 0.74 | CHRNA7 (0.62) | CHRNA7ADRA1AADRA1DADRA1BPOLB | |
| SCHEMBL30363084 | 0.72 | CHRNA7 (0.67) | CHRNA7ADRA1AADRA1DADRA1BPOLB | |
| SCHEMBL2887057 | 0.72 | CHRNA7 (0.67) | CHRNA7ADRA1AADRA1DADRA1BPOLB | |
| SCHEMBL30363160 | 0.72 | CHRNA7 (0.67) | CHRNA7ADRA1AADRA1DADRA1BPOLB | |
| Desbromoarborescidine A SCHEMBL31662855 | 0.71 | CHRNA7 (0.66) | CHRNA7ADRA1AADRA1DADRA1BCYP2D6 | |
| Desbromoarborescidine A SCHEMBL5269957 | 0.71 | CHRNA7 (0.66) | CHRNA7ADRA1AADRA1DADRA1BCYP2D6 | |
| Desbromoarborescidine A SCHEMBL29002756 | 0.71 | CHRNA7 (0.66) | CHRNA7ADRA1AADRA1DADRA1BCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220218677-A1 | ARYLQUINOZILINE DERIVATIVES AS ALPHA2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONISTS FOR THE TREATMENT OF SLEEP APNEA | BAYER AKTIENGESELLSCHAFT (DE) | 2022-07-14 | — | — | US | claimed |
| US-20070293527-A9 | Polycyclic compounds as potent alpha2-adrenoceptor antagonists | ORION CORPORATION (FI) | 2007-12-20 | — | — | US | claimed |
| US-20060094740-A1 | Polycyclic compounds as potent alpha2-adrenoceptor antagonists | DIN BELLE DAVID | 2006-05-04 | — | — | US | claimed |
| US-20220218695-A1 | COMBINATION OF AN ALPHA2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONISTS WITH A TASK1/3 CHANNEL BLOCKER FOR THE TREATMENT OF SLEEP APNEA | BAYER AKTIENGESELLSCHAFT (DE) | 2022-07-14 | — | — | US | disclosed |
| US-20220218677-A1 | ARYLQUINOZILINE DERIVATIVES AS ALPHA2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONISTS FOR THE TREATMENT OF SLEEP APNEA | BAYER AKTIENGESELLSCHAFT (DE) | 2022-07-14 | — | — | US | disclosed |
| US-7592350-B2 | Polycyclic compounds as potent alpha2-adrenoceptor antagonists | ORION CORPORATION (FI) | 2009-09-22 | — | — | US | disclosed |
| US-20070293527-A9 | Polycyclic compounds as potent alpha2-adrenoceptor antagonists | ORION CORPORATION (FI) | 2007-12-20 | — | — | US | disclosed |
| EP-1490361-B1 | POLYCYCLIC COMPOUNDS AS POTENT ALPHA2-ADRENOCEPTOR ANTAGONISTS | ORION CORP (FI) | 2007-10-03 | — | — | EP | disclosed |
| US-20060094740-A1 | Polycyclic compounds as potent alpha2-adrenoceptor antagonists | DIN BELLE DAVID | 2006-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094740-A1 | Polycyclic compounds as potent alpha2-adrenoceptor antagonists | ADRB2, ADRA2A, ADRB1 | CHRNA7 75/4885ADRA1A 6/4885ADRA1D 5/4885 |
| US-20220218695-A1 | COMBINATION OF AN ALPHA2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONISTS WITH A TASK1/3 CHANNEL BLOCKER FOR THE TREATMENT OF SLEEP APNEA | ADRA2C, ADRB2, CHRNA1 | CHRNA7 18/4885ADRA1A 12/4885ADRA1D 5/4885 |
| US-20220218677-A1 | ARYLQUINOZILINE DERIVATIVES AS ALPHA2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONISTS FOR THE TREATMENT OF SLEEP APNEA | ADRA2C, ADRB2, ADRA2A | CHRNA7 19/4885ADRA1A 9/4885ADRA1D 7/4885 |
| US-20070293527-A9 | Polycyclic compounds as potent alpha2-adrenoceptor antagonists | ADRB2, ADRA2A, ADRB1 | CHRNA7 75/4885ADRA1A 6/4885ADRA1D 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.